Results 111 to 120 of about 16,542 (247)

Dupilumab‐Associated Erythema Multiforme‐Like Eruption With Lichenoid Histology in a Paediatric Patient: A Case Report

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Dupilumab‐associated erythema multiforme and lichenoid eruptions have been previously reported as rare dermatological adverse events. We present an atypical paediatric case of a dupilumab‐associated erythema multiforme‐like eruption in a 5‐year‐old male eczema patient, who developed erythematous targetoid papules and plaques over the upper and
Paul Sun Woo Kim, Jacqueline Tu, Kelvin Truong, Gloria Fong, William Luu, Narinder Kaur, Miriam Fewtrell, Li‐Chuen Wong   +7 more
wiley   +1 more source

Long-term outcomes of dupilumab therapy in severe asthma: A retrospective, multicenter, real-world study

Journal of Allergy and Clinical Immunology: Global
Background: Dupilumab is an IL-4Rα antibody approved for treatment of severe asthma. Real-world data on the continuation and cessation patterns of dupilumab and long-term treatment efficacy are scarce.
Carlo Mümmler, MD, Alexandra Lenoir, MD, Jeremias Götschke, MD, Michael Gerckens, MD, Merle Kaiser, MD, Moritz Kayser, MD, Nora Drick, MD, Hendrik Suhling, MD, Leonie Biener, MD, Carmen Pizarro, MD, Dirk Skowasch, MD, Nikolaus Kneidinger, MD, PhD, Jürgen Behr, MD, Katrin Milger, MD   +13 more
doaj   +1 more source

Dupilumab for prurigo nodularis:Case series and review of the literature

, 2020
Dupilumab is a recombinant complete human monoclonal antibody modulating the signaling of interleukin-4 and interleukin-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis.
Agner, Tove, Thomsen, Simon Francis, Holm, Jesper Gronlund, Sand, Carsten   +3 more
core   +1 more source

Dupilumab in Paediatric Netherton Syndrome: Two Case Reports and a Review of the Literature

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Netherton Syndrome (NS) is a rare genodermatosis characterised by a triad of ichthyosiform erythroderma, an atopic diathesis, and trichorrhexis invaginata, for which no effective management is currently approved in Australia. Dupilumab has demonstrated considerable effectiveness in the treatment of atopic conditions in the paediatric ...
Jacqueline Tu, Paul Sun Woo Kim, Kelvin Truong, Gloria Fong, William Luu, Li‐Chuen Wong   +5 more
wiley   +1 more source

Ocular symptoms associated with dupilumab in atopic dermatitis [PDF]

, 2019
BACKGROUND: Dupilumab, the first registered biological for the treatment of atopic dermatitis, frequently causes adverse ocular events. These often take the form of mild conjunctivitis or blepharoconjunctivitis, however, more serious adverse ocular ...
Schuttelaar, Marie L A; id_orcid, Voorberg, Angelique N; id_orcid, Oosterhaven, Jart A F; id_orcid, Wijdh, Robert H J, de Bruin-Weller, Marjolein S   +4 more
core   +2 more sources

Re‐engagement, quality of life, and burden of treatment in adults on dupilumab for severe atopic dermatitis—A mixed methods study

Skin Health and Disease
Background Targeted biologic therapies have revolutionised the treatment of severe atopic dermatitis (AD). Objectives To assess effects of dupilumab on patient re‐engagement, quality of life (QOL), and burden of treatment (BOT) in severe AD.
Emma Porter, Cathal O’Connor, Michelle Murphy   +2 more
doaj   +1 more source

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

Allergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt, Marie Eggers, Nicola M. Tomas, Friedrich Haag, Friedrich Koch‐Nolte, Boris Fehse, Kristoffer Riecken   +16 more
wiley   +1 more source

Suspensión de dupilumab en dermatitis atópica. ¿es una opción la suspensión? Seguimiento de 12 casos

Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
Antecedentes: Dupilumab es el primer tratamiento biológico aprobado para la dermatitis atópica (DA) moderada a severa con excelente perfil de seguridad y eficacia pero hasta el momento con poca literatura sobre la duración de tratamiento.   Objetivo:
Mirian Casas-Vargas, Cindy Cáceres-Salamanca, María Fernanda Ordóñez-Rubiano   +2 more
doaj   +1 more source

Efficacy and Safety of Dupilumab in Chinese Adult Patients With Chronic Rhinosinusitis With Nasal Polyps: A Randomized, Placebo‐Controlled, Phase III Trial

Allergy, EarlyView.
Dupilumab significantly improved nasal polyp score, nasal congestion, olfaction, total symptom score, and disease‐specific quality of life in Chinese patients with uncontrolled CRSwNP. Incidence of treatment‐emergent adverse events was similar between dupilumab and placebo.
Mu Xian, Menglin Wang, Changqing Zhao, Lijia Wan, Yu Xu, Juan Meng, Rui Xu, Xicheng Song, Li Shi, Yucheng Yang, Yan Jiang, Yanzhen Wu, Bethany Ling, Vivian Li, Andrew P. Fontenot, Lacey R. Robinson, Neelam A. Phadke, Chengshuo Wang, Luo Zhang   +18 more
wiley   +1 more source

Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis

Dermatology and Therapy
Summary of the original article “Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis.” Dupilumab is a monoclonal antibody used to treat atopic dermatitis (AD) in patients 6 months and older.
Matthew P. Kosloski, Ching-Ha Lai, Michael A. Partridge, Vanaja Kanamaluru, Ashish Bansal, Brad Shumel, Marius Ardeleanu, Hong Yan, Christine Xu, Ainara Rodríguez Marco, Jing Xiao, Faisal A. Khokhar, Guy Gherardi, Elisa Babilonia, Bolanle Akinlade, Albert Torri, John D. Davis   +16 more
doaj   +1 more source